Stay updated with breaking news from Outlayer Item. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Regenxbio has initiated a second phase 3 pivotal trial investigating RGX-314 in patients with wet age-related macular degeneration, according to a press release.
Cutaneous adverse events appeared largely reversible and rarely led to therapy discontinuation among patients with metastatic melanoma treated with combination checkpoint inhibitors, according to a study in Cancer.Additionally, patients who experienced cutaneous toxicities after treatment with a combination of anti-CTLA-4 and anti-PD-1 therapy had a longer time to next treatment, suggesting a
Pediatric hospitalizations due to COVID-19 reached a peak in recent weeks, according to CDC data.
The No Surprises Act, which officially took effect Jan. 1 as a way to protect patients from unexpected medical bills, already faces several lawsuits from health care organizations.The bill was passed by Congress in 2020 as part of the coronavirus relief package. It was designed to safeguard patients against surprise out-of-network care costs.
Integrated data from the phase 2 ONSET-1 and phase 3 ONSET-2 clinical trials showed that OC-01 nasal spray effectively improves endogenous basal tear production in a heterogeneous dry eye disease population.The results of this analysis were presented in a poster session at the American Academy of Ophthalmology meeting by John Sheppard, MD.